drugset / Trial / NCT00417326

Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia

NCT00417326

Phase 2 Completed 174 enrolled Ono Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of ONO-5046Na in patients with acute respiratory failure associated with community-acquired pneumonia

Timeline

Start
2006-12
Primary completion
2009-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Sivelestat Small molecule 0 mg/kg Intravenous
Subject Sivelestat Small molecule 0.2 mg/kg Intravenous

Indications